Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
BUB1B
REST API REST API
Homo sapiens
BUB1B is differentially expressed in 304 experiments: 110 organism parts: bone marrow, testis, ... (108 more);, 236 disease states: normal, colon carcinoma, ... (234 more);, 92 cell types 314 cell lines 34 compound treatments and 72 other conditions.
Synonyms MAD3L, Bub1A, BUBR1, SSK1
Orthologs BUB1B (Gallus gallus)   BUB1B (Danio rerio)   Bub1b (Mus musculus)   BUB1B (Bos taurus)   ENSCING00000017219 (Ciona intestinalis)   BUB1 (Saccharomyces cerevisiae)   MAD3 (Saccharomyces cerevisiae)   Bub1b (Rattus norvegicus)   BubR1 (Drosophila melanogaster)   Bub1 (Drosophila melanogaster)   bub1b (Xenopus laevis)   BUB1B (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, spindle midzone, anaphase-promoting complex, cell division, M phase of mitotic cell cycle, protein binding, apoptosis, cytoskeleton, kinetochore, cytoplasm, cell proliferation, protein localization to kinetochore, mitotic cell cycle, condensed chromosome kinetochore, spindle organization, anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process, mitotic prometaphase, ATP binding, cell cycle, transferase activity, transferring phosphorus-containing groups, microtubule organizing center, nucleus, mitotic cell cycle checkpoint, mitosis, nucleotide binding, protein serine/threonine kinase activity, perinuclear region of cytoplasm, chromosome, cell cycle checkpoint, mitotic cell cycle spindle assembly checkpoint, protein kinase activity, mitotic metaphase/anaphase transition, negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle, condensed chromosome outer kinetochore, protein phosphorylation, phosphatidylinositol-mediated signaling, regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle
InterPro Term Mad3_BUB1_I, Se/Thr_kinase-like_dom
UniProt Accession C9JLW5, O60566
Gene-Disease Assocation MOSAIC VARIEGATED ANEUPLOIDY SYNDROME 1; MVA1, COLORECTAL CANCER; CRC, PREMATURE CHROMATID SEPARATION TRAIT; PCS
Search EB-eye ENSG00000156970
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-6573, E-GEOD-1577, E-MEXP-433, ... (32 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-4717, ... (39 experiments)

Factor Value U/D Experiments
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
HT1080
2
E-MTAB-37, E-GEOD-20089
MCF-7
2
E-GEOD-20081, E-GEOD-19639
MOLT4
2
E-MTAB-37, E-MTAB-62
WI38
2
E-MTAB-37, E-MTAB-62
PC3
1
2
E-MEXP-2034, E-GEOD-5258, E-GEOD-14464
308 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-4219, E-GEOD-20677, ... (38 experiments)

Factor Value U/D Experiments
CD34+
2
E-AFMX-5, E-TABM-145
2
E-TABM-130, E-TABM-145
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
fibroblast
2
E-GEOD-3920, E-GEOD-3204
endothelial cell
1
2
E-GEOD-19240, E-GEOD-3920, E-GEOD-3998
CD19+ B cells (neg. sel.)
1
E-AFMX-5
86 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-GEOD-1577, E-TABM-15, ... (68 experiments)

Factor Value U/D Experiments
colon carcinoma
4
E-MTAB-62, E-MTAB-37, E-GEOD-3726, E-MTAB-57
glioblastoma
4
E-GEOD-4290, E-GEOD-6014, E-MTAB-37, E-MEXP-567
acute lymphoblastic leukemia
3
E-MTAB-62, E-MTAB-37, E-GEOD-96
prostate carcinoma
3
E-GEOD-96, E-MEXP-2034, E-TABM-26
Duchenne muscular dystrophy
2
E-GEOD-3307, E-GEOD-1004
breast cancer
2
E-MTAB-62, E-GEOD-22544
230 more value(s).


Compound treatment

studied in E-GEOD-571, E-GEOD-7400, E-GEOD-6907, E-GEOD-1417, E-TABM-782, ... (23 experiments)

Factor Value U/D Experiments
none
4
8
E-TABM-782, E-GEOD-5824, E-GEOD-1417, E-GEOD-4600, E-GEOD-412, ... (12 experiments)
lipopolysaccharide
2
E-MEXP-1958, E-GEOD-3720
nocodazole
2
E-GEOD-6431, E-GEOD-571
phenol
1
E-GEOD-6907
glucose
1
E-MEXP-941
arsenic oxide
1
E-GEOD-6907
28 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
LT6
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-2666, ... (7 experiments)

Disease staging
studied in E-GEOD-19743, E-GEOD-22544, E-GEOD-3325, E-MTAB-69, E-TABM-147, ... (6 experiments)

Environmental stress
studied in E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7011, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (9 experiments)

Genotype
studied in E-GEOD-1923, E-MEXP-1437, E-GEOD-3494, E-TABM-321, E-TABM-868, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-22278, E-GEOD-10315, E-TABM-440, E-GEOD-837, ... (15 experiments)

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-2748

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-GEOD-3606, ... (27 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-MEXP-561, E-GEOD-6802

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977, E-TABM-321

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-22152, E-GEOD-21750, E-MEXP-1412, E-GEOD-1657, ... (8 experiments)

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10797, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (9 experiments)

Sample preparation
studied in E-GEOD-16728

Sampling time point
studied in E-GEOD-19743, E-MEXP-70, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19069, E-GEOD-7307, E-GEOD-16363

Stimulation
studied in E-GEOD-4883, E-GEOD-11886, E-GEOD-11428

Strain or line
studied in E-TABM-125

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276, E-GEOD-2748

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815, E-GEOD-15799, ... (6 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 99 146
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-3494, E-GEOD-1561, E-GEOD-6532, E-GEOD-4922, ... (6 experiments)

Processing time: 0.442 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM